ES2184792T3 - Poliqueladores. - Google Patents

Poliqueladores.

Info

Publication number
ES2184792T3
ES2184792T3 ES95910609T ES95910609T ES2184792T3 ES 2184792 T3 ES2184792 T3 ES 2184792T3 ES 95910609 T ES95910609 T ES 95910609T ES 95910609 T ES95910609 T ES 95910609T ES 2184792 T3 ES2184792 T3 ES 2184792T3
Authority
ES
Spain
Prior art keywords
sup
preferibly
sub
domain
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95910609T
Other languages
English (en)
Inventor
Lawrence Margerum
Joan Carvalho
Martha Garrity
Jere Douglas Fellmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amersham Health Salutar Inc
Original Assignee
Amersham Health Salutar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Health Salutar Inc filed Critical Amersham Health Salutar Inc
Application granted granted Critical
Publication of ES2184792T3 publication Critical patent/ES2184792T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D259/00—Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/16—Dendrimers and dendritic polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polyethers (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

ESTA INVENCION CONSISTE EN COMPUESTOS POLIQUELANTES QUE RESULTAN UTILES, POR EJEMPLO, EN LOS PROCEDIMIENTOS DE DIAGNOSTICO POR IMAGENES Y QUE SON DEGRADABLES IN VIVO Y PRODUCEN FRAGMENTOS EXCRETABLES. ESTOS COMPUESTOS TIENEN UNA FORMULA (I): R{SUP,1}(X{SUP,1}R{SUP,2}((X{SUP,2}){SUB,P}L){SUB,N}){SUB,M} (DONDE X{SUP,1} ES UN DOMINIO DE ENLACE METABOLICAMENTE FRAGMENTABLE PARA PRODUCIR R{SUP,1}X{SUP,3}{SUB,M} Y X{SUP,4}R{SUP,2}((X{SUP,2}){SUB,P}L){SUB,N}, DONDE X{SUP,3} Y X{SUP,4} SON LOS RESIDUOS DE LA FRAGMENTACION DE X{SUP,1}; R{SUP,1}X{SUP,3}{SUB,M} ES UN POLIMERO BIOTOLERADO, PREFERIBLEMENTE UN POLIMERO BASICAMENTE MONODISPERSO Y EN ESPECIAL, UNO CON UN PESO MOLECULAR INFERIOR A 40.000 D, PREFERIBLEMENTE INFERIOR A 30.000 D, Y ESPECIALMENTE, INFERIOR A 20.000 D, POR EJEMPLO, UN DENDRIMERO DE LA PRIMERA A LA SEXTA GENERACION. X{SUP,4}R{SUP,2}((X{SUP,2}){SUB,P}L){SUB,N} ES UN FRAGMENTO POLIQUELANTE CON UN PESO MOLECULAR INFERIOR A 40.000 D, PREFERIBLEMENTE INFERIOR A 30.000 D, Y ESPECIALMENTE, INFERIOR A 20.000 D, EN EL QUE CADA DOMINIO ES PREFERIBLEMENTE EL MISMO; P ES 0 O 1; X{SUP,2}, CUANDO EXISTEN ES UN DOMINIO DE ENLACE METABOLICAMENTE FRAGMENTABLE QUE PRODUCE UN FRAGMENTO MONOQUELANTE. CADA L ES UN DOMINIO QUELANTE MACROCICLICO, EN EL QUE EL ESQUELETO MACROCICLICO TIENE PREFERIBLEMENTE ENTRE 9 Y 25 ELEMENTOS EN EL ANILLO Y, PREFERIBLEMENTE, ES UN POLIAZACICLOALCANO INTERRUMPIDO POR OXIGENO O AZUFRE. R{SUP,2}((X{SUP,2}){SUB,P}){SUB,N} ES UNA CADENA LINEAL O UN DOMINIO RAMIFICADO, PREFERIBLEMENTE CON UNA CADENA DE HASTA 20 ATOMOS ENTRE CADA GRUPO L Y EL DOMINIO X{SUP,1} AL QUE ESTA UNIDO, Y UNA CADENA DE HASTA 25 ATOMOS ENTRE CADA PAR DE GRUPOS L UNIDOS POR ELLA. ESTAS CADENAS DEBERIAN SER CADENAS DE CARBONOS INTERRUMPIDAS POR NITROGENO, OXIGENO O AZUFRE. CADA N ES UN ENTERO CON UN VALOR DE AL MENOS 2, Y PREFERIBLEMENTE UN VALOR ENTRE 2 Y 25, ESPECIALMENTE ENTRE 2 Y 12 U CADA M ES UN ENTERO CON UN VALOR DE AL MENOS 2, PREFERIBLEMENTE UN VALOR INFERIOR A 200 Y ESPECIALMENTE ENTRE 3 Y 100, DE MANERA QUE EL NUMERO TOTAL DE GRUPOS L EN EL POLIQUELANTE DE FORMULA (I) ES 20, Y PREFERIBLEMENTE, DE 50 A 200). LOS COMPUESTOS TIENEN UN PESO MOLECULAR DE AL MENOS 30.000 D, PREFERIBLEMENTE DE AL MENOS 40.000 D, Y, EN EL MEJOR DE LOS CASOS, ENTRE 50.000 Y 150.000 D Y CONTIENEN, ADEMAS, QUELANTES METALICOS Y SALES DE ESTOS.
ES95910609T 1994-03-04 1995-03-03 Poliqueladores. Expired - Lifetime ES2184792T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9404208A GB9404208D0 (en) 1994-03-04 1994-03-04 Chelants

Publications (1)

Publication Number Publication Date
ES2184792T3 true ES2184792T3 (es) 2003-04-16

Family

ID=10751305

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95910609T Expired - Lifetime ES2184792T3 (es) 1994-03-04 1995-03-03 Poliqueladores.

Country Status (11)

Country Link
US (1) US5976493A (es)
EP (1) EP0748229B1 (es)
JP (1) JPH09510239A (es)
CN (1) CN1139882A (es)
AU (1) AU1852995A (es)
CA (1) CA2181070A1 (es)
DE (1) DE69528046T2 (es)
ES (1) ES2184792T3 (es)
GB (1) GB9404208D0 (es)
MX (1) MX9603679A (es)
WO (1) WO1995024225A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
DE19525924A1 (de) 1995-07-04 1997-01-09 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US6166200A (en) * 1995-07-04 2000-12-26 Schering Aktiengesellschaft Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes
US5874061A (en) * 1995-12-22 1999-02-23 Schering Aktiengesellschaft Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes
DE19549286A1 (de) * 1995-12-22 1997-06-26 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
EP1032430A2 (en) 1997-11-17 2000-09-06 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
US6361759B1 (en) * 1998-05-26 2002-03-26 Wisconsin Alumni Research Foundation MR signal-emitting coatings
US6896874B2 (en) 1998-05-26 2005-05-24 Wisconsin Alumni Research Foundation MR-signal emitting coatings
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
AU2002350991A1 (en) * 2001-06-25 2003-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Macromolecular imaging agents for liver imaging
ITMI20011708A1 (it) * 2001-08-03 2003-02-03 Bracco Imaging Spa Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
US7199268B2 (en) 2003-12-16 2007-04-03 Schering Aktiengesellschaft Process for the production of dendritic trimesic acid triamides
US20060204443A1 (en) * 2005-03-11 2006-09-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for tumor treatment using dendrimer conjugates
US8457712B2 (en) 2005-12-30 2013-06-04 Wisconsin Alumni Research Foundation Multi-mode medical device system and methods of manufacturing and using same
US8532742B2 (en) 2006-11-15 2013-09-10 Wisconsin Alumni Research Foundation System and method for simultaneous 3DPR device tracking and imaging under MR-guidance for therapeutic endovascular interventions
US8412306B2 (en) 2007-02-28 2013-04-02 Wisconsin Alumni Research Foundation Voltage standing wave suppression for MR-guided therapeutic interventions
US20090169480A1 (en) * 2007-12-31 2009-07-02 Industrial Technology Research Institute Dendritic polymers and magnetic resonance imaging contrast agent employing the same
JP6032729B2 (ja) * 2012-05-08 2016-11-30 国立研究開発法人理化学研究所 イメージングマーカーおよびその利用
RU2528414C1 (ru) 2013-01-25 2014-09-20 Закрытое Акционерное Общество "Фарм-Синтез" Циклический октапептид, радиофармацевтическое средство на его основе и способ применения радиофармацевтического средства для получения лекарственных (фармацевтических) средств для лечения новообразований, экспрессирующих соматостатиновые рецепторы
EP3887033B1 (en) * 2018-11-28 2024-07-24 Cube Biotech GmbH Solid-phase chelator material, method for producing thereof and use thereof for the purification of proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338532A (en) * 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
US5914095A (en) * 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
CA2069886A1 (en) * 1989-10-23 1991-04-24 David Love Multi-site metal chelating agents
DE3938992A1 (de) * 1989-11-21 1991-05-23 Schering Ag Kaskadenpolymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4115789A1 (de) * 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
GB9318550D0 (en) * 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants

Also Published As

Publication number Publication date
CN1139882A (zh) 1997-01-08
MX9603679A (es) 1997-06-28
US5976493A (en) 1999-11-02
CA2181070A1 (en) 1995-09-14
GB9404208D0 (en) 1994-04-20
EP0748229B1 (en) 2002-09-04
AU1852995A (en) 1995-09-25
DE69528046D1 (de) 2002-10-10
WO1995024225A1 (en) 1995-09-14
JPH09510239A (ja) 1997-10-14
EP0748229A1 (en) 1996-12-18
DE69528046T2 (de) 2003-04-24

Similar Documents

Publication Publication Date Title
ES2184792T3 (es) Poliqueladores.
ES2063786T3 (es) Eteres polifenilenicos protegidos terminalmente con epoxitrizina y procedimiento de preparacion.
ES2099280T3 (es) Complejos macrociclicos de tierras raras y su utilizacion para reducir las interferencias en un dosificado por fluorescencia.
ES2128069T3 (es) Productos de reaccion, formados por poliisobutenos y oxidos de nitrogeno o mezclas, constituidas por oxidos de nitrogeno y oxigeno y su empleo como aditivos para combustibles y lubricantes.
MX166092B (es) Composicion de cemento con resistencia mejorada y procedimiento para aumentar la resistencia de mezclas de cementos hidraulicos
ES2145115T3 (es) Composiciones inyectables a base de derivados de taxanos.
CO4480055A1 (es) Mezcla de poliester/poliamida con propiedad de retencion de sabor y claridad mejorada
ES2110003T3 (es) Nuevas composiciones a base de derivados de la clase de los taxanos.
ES2175985T3 (es) Acero de cementacion a temperatura de revenido elevada, procedimiento para su obtencion y piezas formadas con dicho acero.
AR032630A1 (es) Una composicion de grasa que comprende un aceite base y un espesante, uso de la misma y un metodo para prepararla
ES2164265T3 (es) Unidades monomericas utiles para reducir el modulo de hidrogeles de silicona.
PA8497801A1 (es) Conjugados de eritropoyetina
ES2183782T3 (es) Material de sutura para heridas a base de metilideno malonato.
ES2110556T3 (es) Procedimiento para estabilizar ligandos de fosfito.
ES2139383T3 (es) Complejos metalicos soportados facilmente.
ES2094974T3 (es) Derivados de 17-aril- y 17-heterociclil-14beta-5alfa-androstano, androsteno y androstadieno, activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos.
AR009089A1 (es) Composiciones para el cuidado del color que comprenden un agente fijador de colorante y un polimero y un metodo para proporcionar cuidado de color
ES2116030T3 (es) Composicion de grasa lubricante.
ES2136123T3 (es) Derivado de silicona modificado por el fluor; produccion de este derivado y cosmetico que los contiene.
AR032574A1 (es) Conjugados peg de hgf-nk4
CY1106449T1 (el) Βελτιωμενη μεθοδος για εκριζωση του helicobacter pylori
ES2099422T3 (es) Derivados de avermectina y milbemicina antiparasitarios.
ES2040363T3 (es) Procedimiento para la obtencion de derivados aromaticos.
BR0315178A (pt) Eritropoietina: remodelagem e glicoconjugação de eritropoietina
ES2172297T3 (es) Aumento de peso molecular y estabilizacion de policondensados con diepoxidos de aminas impedidas estericamente.